OverviewSuggest Edit

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers an alternative to existing drug modalities for a wide range of disease conditions.

TypePublic
HQCambridge, MA, US
Websitemodernatx.com
Employee Ratings4.1
Overall CultureD-

Latest Updates

Employees (est.) (Dec 2019)830(+10%)
Job Openings492
Revenue (FY, 2020)$803.4 M(+1235%)
Share Price (Jul 2021)$321.1(+5%)
Cybersecurity ratingAMore

Key People/Management at Moderna

Stephane Bancel

Stephane Bancel

Chief Executive Officer, Director
Paul Sagan

Paul Sagan

Director
Stephen Hoge

Stephen Hoge

President
Henri A. Termeer

Henri A. Termeer

Director
Tracey Franklin

Tracey Franklin

Chief Human Resources Officer
Stephen Berenson

Stephen Berenson

Director
Show more

Moderna Office Locations

Moderna has offices in Cambridge, Norwood and Huddinge
Cambridge, MA, US (HQ)
200 Technology Square
Cambridge, MA, US
NE47, 500 Technology Square
Norwood, MA, US
100 Upland Rd
Huddinge, SE
Hälsovägen 7-9
Show all (4)

Moderna Financials and Metrics

Moderna Revenue

Moderna's revenue was reported to be $803.4 m in FY, 2020
USD

Revenue (Q1, 2021)

1.9b

Gross profit (Q1, 2021)

1.7b

Gross profit margin (Q1, 2021), %

90%

Net income (Q1, 2021)

1.2b

EBIT (Q1, 2021)

1.3b

Market capitalization (21-Jul-2021)

128.9b

Closing stock price (21-Jul-2021)

321.1

Cash (31-Mar-2021)

5.4b

EV

123.7b
Moderna's current market capitalization is $128.9 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

108.4m205.8m135.1m60.2m803.4m

Revenue growth, %

90%

Cost of goods sold

7.9m

Gross profit

795.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

16.0m13.1m17.0m8.4m28.4m145.7m1.9b

Cost of goods sold

193.0m

Gross profit

1.7b

Gross profit Margin, %

90%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

50.1m134.9m658.4m235.9m2.6b

Accounts Receivable

13.4m11.9m11.7m5.0m1.4b

Prepaid Expenses

15.5m12.8m28.4m19.4m252.2m

Inventories

46.5m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

167.1m502.9m151.6m173.7m391.7m1.8b1.5b5.4b

Accounts Receivable

9.8m5.6m3.5m2.8m5.6m33.4m190.5m3.2b

Prepaid Expenses

33.4m25.3m23.9m45.3m109.4m264.0m

Inventories

494.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(216.2m)(255.9m)(514.0m)(747.1m)

Depreciation and Amortization

17.6m21.6m24.9m31.0m

Inventories

(46.5m)

Accounts Payable

6.0m(12.8m)15.0m(24.0m)11.9m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(243.3m)(218.0m)(132.7m)(267.7m)(390.9m)(124.2m)(240.9m)(474.6m)1.2b

Depreciation and Amortization

58.4m43.6m7.3m14.8m22.1m15.0m15.0m

Inventories

(448.0m)

Accounts Payable

718.0k(9.9m)1.7m(1.5m)(19.2m)2.3m11.5m13.6m(15.0m)
USDFY, 2016

Revenue/Employee

302.9k

Financial Leverage

-4.2 x
Show all financial metrics

Moderna Operating Metrics

Moderna's Clinical Programs was reported to be 10 in Q3, 2018.
Y, 2015May, 2017Q3, 2018

Clinical Programs

10

Drugs in Development

92

Patent Applications

250

Patents Issued

100
Show all operating metrics

Moderna Acquisitions / Subsidiaries

Company NameDateDeal Size
Brizo
Moderna AB
Moderna Securities
ModernaTX

Moderna Revenue Breakdown

Embed Graph

Moderna revenue breakdown by business segment: 14.0% from Grant revenue, 14.6% from Collaboration revenue from affiliate and 71.4% from Collaboration revenue

Moderna Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Moderna Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Moderna Online and Social Media Presence

Embed Graph

Moderna Company Culture

  • Overall Culture

    D-

    51/100

  • CEO Rating

    D-

    60/100

  • Compensation

    C+

    73/100

Learn more on Comparably

Moderna News and Updates

Moderna would never release coronavirus vaccine data different from 'reality,' chairman says

The company put out the extent of data it had available, Moderna Chairman Noubar Afeyan tells CNBC.

Morgan Stanley now sees Moderna shares spiking 26% from current levels, cites 65% chance of success for virus vaccine (MRNA)

Morgan Stanley raised its Moderna price target to $90 from $37, citing "initial promising Covid-19 vaccine data," according to a Wednesday note.  That's a 26% jump from where shares of Moderna currently trade.  The bank risk-adjusted its estimates following the early results of the vaccine and no…

Lonza CEO says on pace to make Moderna trial vaccine in June/July - CNBC

Contract drug manufacturer Lonza still expects to supply drugmaker Moderna with active ingredients for its experimental COVID-19 vaccine by June or July to support laboratory trials, the Swiss company's interim CEO, Albert Baehny, told CNBC on Wednesday.

Dow futures struggle for direction Tuesday evening after Moderna vaccine report sparks Dow's 390-point skid

U.S. stock-index futures ticked higher in thinly traded bumpy action Tuesday evening after the Dow snapped a three-session win streak in the last hour of the regular session, following a report that cast doubt on a coronavirus remedy. Futures for the Dow Jones Industrial Average rose 0.2% at 24,194…

Scientists Raise Questions About Moderna Vaccine In Market-Shaking Report

They have to publish a scientific paper, opting for issuing press releases instead.

Stocks making the biggest moves after hours: Urban Outfitters, Moderna, Johnson & Johnson and more

Check out the companies making headlines after the bell.
Show more

Moderna Blogs

Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus Content Import Mon, 03/16/2020 - 12:42 Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus …

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

This pre-clinical study shows that an mRNA RSV vaccine elicited both neutralizing antibodies and robust cellular immune response in rodent models of RSV infection and suggests mRNA vaccines may improve immune responses through presentation of antigens that better mimics what is observed during natu…

Disease pharmacokinetic‐pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA‐based therapies

This publication outlines a translational modeling framework that can be used to describe the effects of mRNA therapy for acute intermittent porphyria (AIP) in preclinical models and support development in humans. Publication Date:  Wednesday, March 11, 2020 Is Featured:  Modalties: Systemic Ther…

Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study

Phase 2 interim data at three months, expected in 3Q 2020, intended to inform Phase 3 dose selection Pivotal Phase 3 study manufacturing and planning underway; study start expected in 2021 CMV is the most common infectious cause of birth defects in the U.S.

Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event

Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event Content Import Mon, 03/02/2020 - 19:37 Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event March 2, 2020 at 7:37 PM EST This release is a ba…

Moderna to Host Manufacturing & Digital Day on March 4, 2020

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2020-- Moderna, Inc. , (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a Manufacturing
Show more

Moderna Frequently Asked Questions

  • Who are Moderna key executives?

    Moderna's key executives are Stephane Bancel, Paul Sagan and Stephen Hoge.

  • How many employees does Moderna have?

    Moderna has 830 employees.

  • What is Moderna revenue?

    Latest Moderna annual revenue is $803.4 m.

  • What is Moderna revenue per employee?

    Latest Moderna revenue per employee is $967.9 k.

  • Who are Moderna competitors?

    Competitors of Moderna include Celyad, CureVac and Regulus Therapeutics.

  • Where is Moderna headquarters?

    Moderna headquarters is located at 200 Technology Square, Cambridge.

  • Where are Moderna offices?

    Moderna has offices in Cambridge, Norwood and Huddinge.

  • How many offices does Moderna have?

    Moderna has 4 offices.